U.S. Markets close in 6 hrs 21 mins

ZIOPHARM Oncology (NASDAQ:ZIOP) Shareholders Have Enjoyed A 21% Share Price Gain

Simply Wall St

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

Passive investing in index funds can generate returns that roughly match the overall market. But you can significantly boost your returns by picking above-average stocks. To wit, the ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) share price is 21% higher than it was a year ago, much better than the market return of around 0.7% (not including dividends) in the same period. If it can keep that out-performance up over the long term, investors will do very well! Zooming out, the stock is actually down 10.0% in the last three years.

See our latest analysis for ZIOPHARM Oncology

While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).

ZIOPHARM Oncology went from making a loss to reporting a profit, in the last year. The result looks like a strong improvement to us, so we're not surprised the market likes the growth. Generally speaking the profitability inflection point is a great time to research a company closely, lest you miss an opportunity to profit.

The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image).

NasdaqCM:ZIOP Past and Future Earnings, June 17th 2019

We're pleased to report that the CEO is remunerated more modestly than most CEOs at similarly capitalized companies. But while CEO remuneration is always worth checking, the really important question is whether the company can grow earnings going forward. Dive deeper into the earnings by checking this interactive graph of ZIOPHARM Oncology's earnings, revenue and cash flow.

A Different Perspective

We're pleased to report that ZIOPHARM Oncology shareholders have received a total shareholder return of 21% over one year. That's better than the annualised return of 3.6% over half a decade, implying that the company is doing better recently. Someone with an optimistic perspective could view the recent improvement in TSR as indicating that the business itself is getting better with time. Before spending more time on ZIOPHARM Oncology it might be wise to click here to see if insiders have been buying or selling shares.

But note: ZIOPHARM Oncology may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.